Codexis, Inc. discovers, develops, and sells enzymes and other proteins.
If you are interested in CDXS stock information, you might also be interested in competitors like LSE:JMAT.
With a P/E ratio of 0.00, the stock appears relatively cheap compared to its index ^SPX at the moment.
The market capitalization of Codexis is currently at $0.57 B. This places it among the low capitalized companies.
The book value reported in the balance sheet results in a P/B ratio of 3.23.
With one share of Codexis investors achieved a dividend of $0.00. This results in a very low dividend yield of 0.00%.
For the risk analysis, the high beta factor should be noted, which is currently at a value of 1.60. The price of the stock NasdaqGS:CDXS is therefore subject to relatively strong fluctuations in relation to the overall market.
7.52% of CDXS Stocks is owned by insiders.
For Wall Street analysts, a price target of $22.25 is currently considered realistic.
NasdaqGS:CDXS has a 52 week range of $6.15 - $42.01 and is currently trading around $7.84.
The low short sale ratio indicated that the value might increase in the foreseeable future.